Charts
Stock events calendar
Vaccine stocks news
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Phreesia, Inc. ("Phreesia") (NYSE:PHR) concerning possible violations of federal securities laws. Phreesia issued a press release on May 30, 2024, announcing financial results for the first quarter of its fiscal year 2025.
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. ("Phreesia" or the "Company") (NYSE: PHR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks.
Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans.
Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans.
Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth. Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute. With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
Nvidia (NASDAQ: NVDA ) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami.